Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.4631
- Book/Share 32.4389
- PB 5.1562
- Debt/Equity 0.6469
- CurrentRatio 1.0059
- ROIC 0.1216
- MktCap 402818948400.0
- FreeCF/Share 6.7781
- PFCF 24.5666
- PE 17.8553
- Debt/Assets 0.2625
- DivYield 0.03
- ROE 0.3039
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
Published: February 24, 2025 by: Reuters
Sentiment: Negative
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.
Read More
Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
The latest trading day saw Johnson & Johnson (JNJ) settling at $157.89, representing a +1.87% change from its previous close.
Read More
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of consensus and expense guidance was surprisingly low, indicating only 7% growth, and enhancing the company's financial outlook. J&J's decision on GEN3014 is pending; I expect J&J to opt out, but remain bullish on Genmab's product portfolio, pipeline, and growth prospects.
Read More
Johnson & Johnson: Rich History Of Excellence Poised To Endure
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson offers a compelling balance of growth, innovation, and shareholder returns. JNJ's robust financials, including a fortress-like balance sheet and consistent dividends, support its ability to drive growth and innovation. The company is well-diversified across thriving healthcare segments, with promising FDA approvals and strategic M&A initiatives enhancing its market position.
Read More
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
Read More
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Published: February 13, 2025 by: New York Post
Sentiment: Negative
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson. ("J&J" or the "Company") (NYSE: JNJ).
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100